ACE1-I/D Polymorphism in Patients With Severe COVID-19

Author(s):
Fouzieh KarimiFouzieh Karimi1,*, Vahedeh HosseiniVahedeh Hosseini2, Abbas AhmadiAbbas Ahmadi2, Fahimeh Ranjbar KermaniFahimeh Ranjbar Kermani1, Shirin FerdowsiShirin Ferdowsi1
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
2Cellular and Molecular Research Center, Research Institute for health development & Department of Molecular Medicine and Genetics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
*Corresponding Author: Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran Email: [email protected]

Journal of Cellular & Molecular Anesthesia:Vol. 8, issue 3; e149285
Published online:Feb 28, 2023
Article type:Research Article
How to Cite:Karimi F, Hosseini V, Ahmadi A, Kermani FR, Ferdowsi S. ACE1-I/D Polymorphism in Patients With Severe COVID-19. J Cell Mol Anesth. 2023;8(3):e149285. doi: https://doi.org/10.22037/jcma.v8i3.40994

Abstract

Background: In several studies, insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme 1 (ACE1) gene is described as a genetic risk factor for coronavirus disease 2019 (COVID-19) infection. However, in some studies, this contribution is not confirmed. Therefore, this study aimed to evaluate the genotypic and allelic frequency of ACE1-D/I in Kurdish patients with severe COVID-19 in Iran. Methods: A total of 95 patients with PCR positive-COVID-19 were enrolled in this cross-sectional study. Genomic DNA was extracted from peripheral blood leucocytes using the salting out method. All cases were genotyped for ACE1-I/D polymorphism using polymerase chain reaction (PCR). Death percentage from COVID-19 after two months? follow-up was analyzed.?Results: Of?the 95 patients, 48 were female (50.5%) and 47 were male (49.5%) with a mean age of 61.9?18.7 years. The ID genotype was the most prevalent (52.6%) followed by DD (32.6%) and II (14.7%). The D and I allele frequencies were 58.9%, and 41.1%, respectively. The D allele frequency was higher in patients with SpO2?90% (P = 0.048). The mortality percentage was 18.9% (8 females and 10 males). The frequency of the DD, ID, and II genotypes in patients who died from COVID-19 was 27.7%, 61,1%, and 11.1%. Conclusions: Our results indicated that the ACE1- D allele can be a genetic risk factor in COVID-19 patients. Further studies on different ethnicities and geographical regions are needed to evaluate this polymorphism in COVID-19 infection.

Copyright

© 2023, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

31
Oct
2024
Jundishapur J Microbiol

A Multicentric Study of ACE2 rs2285666 Polymorphism: The Association with COVID-19 in the Iranian Population

Hadi Razavi Nikoo,
Seyed Majid Fatahi,
Mahdieh Taheri,
Mohammad Jamshidi,
Ali Safarzadeh,
Ashkan Alamdary
,et al.

Razavi Nikoo H, Fatahi SM, Taheri M, Jamshidi M, Safarzadeh A, et al. A Multicentric Study of ACE2 rs2285666 Polymorphism: The Association with COVID-19 in the Iranian Population. Jundishapur J Microbiol. 2024;17(10):e153765. doi: https://doi.org/10.5812/jjm-153765

19
Oct
2021

Effect Of Angiotensin-Converting Enzyme Inhibitors And Angiotensin Receptor Blockers On the Clinical Outcome In COVID-19 Patients With Hypertension

Zahra Fakhrae,
Saeid Bitaraf,
Roohangize Nashibi,
Fatemeh Ahmadi,
Safoura Khosravi,
Shokrollah Salmanzadeh

Fakhrae Z, Bitaraf S, Nashibi R, Ahmadi F, Khosravi S, et al. Effect Of Angiotensin-Converting Enzyme Inhibitors And Angiotensin Receptor Blockers On the Clinical Outcome In COVID-19 Patients With Hypertension. J Cell Mol Anesth. 2021;6(4):e149739. doi: https://doi.org/10.22037/jcma.v6i4.35596

19
Sep
2022
Trends in Med Sci

ACE2 in SARS-CoV-2-Mediated COVID-19: A Brief Review

Pooria Safarzadeh Kozani,
Setareh Dashti Shokoohi,
Narges Baharifar,
Sepideh Sheikhi,
Fatemeh Khalaf Shamsabadi,
Forough Chamaie Nejad
,et al.

Safarzadeh Kozani P, Dashti Shokoohi S, Baharifar N, Sheikhi S, Khalaf Shamsabadi F, et al. ACE2 in SARS-CoV-2-Mediated COVID-19: A Brief Review. J Adv Immunopharmacol. 2022;2(4):e130682. doi: https://doi.org/10.5812/tms-130682

24
Aug
2024
Arch Clin Infect Dis

Biochemical Risk Factors of Atherosclerosis in Patients with Severe and Non-severe COVID-19

Maryam Shahali,
Ashkan Alamdary,
Alireaza Gholami,
Rasul Moukhah,
Seyed Dawood Mousavi-Nasab,
Mohammad Javad Hossein Tehrani
,et al.

Shahali M, Alamdary A, Gholami A, Moukhah R, Mousavi-Nasab SD, et al. Biochemical Risk Factors of Atherosclerosis in Patients with Severe and Non-severe COVID-19. Arch Clin Infect Dis. 2024;19(4):e144661. doi: https://doi.org/10.5812/archcid-144661

20
Apr
2022
Ann Mil Health Sci Res

Evaluation of Mutation in Spike Gene of Covid-19 in Iranian Patients

Mohammad Gholami,
Negin Hosseini Rouzbahani,
Hamed Naghoosi,
Sajad Fani-Kheshti,
Seyyed-Javad Hosseini-Shokouh

Gholami M, Hosseini Rouzbahani N, Naghoosi H, Fani-Kheshti S, Hosseini-Shokouh S. Evaluation of Mutation in Spike Gene of Covid-19 in Iranian Patients. Ann Mil Health Sci Res. 2022;20(1):e123942. doi: https://doi.org/10.5812/amh-123942

Download PDF890.99 KB
Indexed in

Crossmark

Crossmark

Checking

Share on
Cited by
Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC 

Search Relations

Author(s):

Related Articles